Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
25.40B
Market cap25.40B
Price-Earnings ratio
16.20
Price-Earnings ratio16.20
Dividend yield
Dividend yield
Average volume
2.28M
Average volume2.28M
High today
$122.67
High today$122.67
Low today
$118.44
Low today$118.44
Open price
$122.19
Open price$122.19
Volume
1.77M
Volume1.77M
52 Week high
$132.60
52 Week high$132.60
52 Week low
$73.81
52 Week low$73.81

Stock Snapshot

The current Incyte(INCY) stock price is $119.52, with a market capitalization of 25.4B. The stock trades at a price-to-earnings (P/E) ratio of 16.20.

On 2026-07-31, Incyte(INCY) stock traded between a low of $118.44 and a high of $122.67. Shares are currently priced at $119.52, which is +0.9% above the low and -2.6% below the high.

The Incyte(INCY)'s current trading volume is 1.77M, compared to an average daily volume of 2.28M.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $73.81.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $73.81.

INCY News

TipRanks 1d
Incyte price target raised to $120 from $110 at JPMorgan

JPMorgan raised the firm’s price target on Incyte (INCY) to $120 from $110 and keeps a Neutral rating on the shares. Unlock powerful investing tools with TipRa...

Simply Wall St 2d
Incyte Wins European Approval For Opzelura In Adult Atopic Dermatitis

Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults. This is Opzelura's second indicati...

Incyte Wins European Approval For Opzelura In Adult Atopic Dermatitis
Benzinga 2d
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results - Benzinga

...

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results - Benzinga

Analyst ratings

57%

of 30 ratings
Buy
40%
Hold
56.7%
Sell
3.3%

More INCY News

Nasdaq 3d
Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio....

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance
TipRanks 3d
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontin...

Nasdaq 4d
Incyte Q2 Earnings and Revenues Top Estimates

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per...

Incyte Q2 Earnings and Revenues Top Estimates
Simply Wall St 4d
Incyte In Focus On Trial Results And Vega Deal As Valuation Questions Persist

Advertisement Why Incyte Stock Is Back in Focus Incyte (INCY) is back on investor watchlists after publishing full safety and efficacy results from its Phase...

Incyte In Focus On Trial Results And Vega Deal As Valuation Questions Persist

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.